|
KMID : 1030220220230030153
|
|
Journal of Korean Diabetes
2022 Volume.23 No. 3 p.153 ~ p.156
|
|
|
Extent of Role: Anti-Diabetic Medications
|
|
Hong Jun-Hwa
|
|
|
Abstract
|
|
|
|
In management of diabetes, glucose lowering is the basic target of treatment. Insulin is essential to type 1 diabetes. Non-insulin therapy in type 2 diabetes is very diverse and continuously developing to improve glucose control and prevent diabetes-related complications. In the recent 30 years, recommended specifications of anti-diabetic drugs are high glucose-lowering efficacy, low risk of hypoglycemia, less burden of weight gain, and cardiovascular safety. With development of SGLT2 inhibitors (sodium glucose cotransporter 2 inhibitors) and GLP-1RA (glucagon-like peptide-1 receptor agonist), the clinical benefits also include risk reduction of diabetes-related complications (hospitalization for heart failure, chronic kidney disease, atherosclerotic cardiovascular disease), even in non-diabetic patients. Anti-diabetic medication can have a role in holistic management for prevention and treatment of diabetes and diabetes-related complications, as well as an improvement of mortality.
|
|
|
KEYWORD
|
|
|
Complications, Diabetes mellitus, type 2, Glucose, Mortality
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|